BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29350409)

  • 1. Comparison of lesional skin c-KIT mutations with clinical phenotype in patients with mastocytosis.
    Chan IJ; Tharp MD
    Clin Exp Dermatol; 2018 Jun; 43(4):416-422. PubMed ID: 29350409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior.
    Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J
    J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.
    Longley BJ; Metcalfe DD; Tharp M; Wang X; Tyrrell L; Lu SZ; Heitjan D; Ma Y
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1609-14. PubMed ID: 9990072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
    Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
    J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of KIT activating mutations in paediatric solitary mastocytoma.
    Ma D; Stence AA; Bossler AB; Hackman JR; Bellizzi AM
    Histopathology; 2014 Jan; 64(2):218-25. PubMed ID: 24128084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis.
    Chan IJ; Kasprowicz S; Tharp MD
    Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation.
    Yanagihori H; Oyama N; Nakamura K; Kaneko F
    J Mol Diagn; 2005 May; 7(2):252-7. PubMed ID: 15858149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
    Divekar R; Butterfield J
    Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.
    Bodemer C; Hermine O; Palmérini F; Yang Y; Grandpeix-Guyodo C; Leventhal PS; Hadj-Rabia S; Nasca L; Georgin-Lavialle S; Cohen-Akenine A; Launay JM; Barete S; Feger F; Arock M; Catteau B; Sans B; Stalder JF; Skowron F; Thomas L; Lorette G; Plantin P; Bordigoni P; Lortholary O; de Prost Y; Moussy A; Sobol H; Dubreuil P
    J Invest Dermatol; 2010 Mar; 130(3):804-15. PubMed ID: 19865100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-kit Asp-816-Val mutation analysis in patients with mastocytosis.
    Verzijl A; Heide R; Oranje AP; van Schaik RH
    Dermatology; 2007; 214(1):15-20. PubMed ID: 17191042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
    Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
    Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
    Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular defects in mastocytosis: KIT and beyond KIT.
    Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
    Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis.
    Cairoli R; Grillo G; Beghini A; Cornacchini G; Larizza L; Morra E
    Hematol J; 2004; 5(3):273-5. PubMed ID: 15167915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
    Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
    Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.
    Akin C; Kirshenbaum AS; Semere T; Worobec AS; Scott LM; Metcalfe DD
    Exp Hematol; 2000 Feb; 28(2):140-7. PubMed ID: 10706069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-kit mutational analysis in paraffin material.
    Sotlar K
    Methods Mol Biol; 2013; 999():59-78. PubMed ID: 23666690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
    Taylor ML; Dastych J; Sehgal D; Sundstrom M; Nilsson G; Akin C; Mage RG; Metcalfe DD
    Blood; 2001 Aug; 98(4):1195-9. PubMed ID: 11493470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.